Author:
Pons-Tostivint Elvire,Thibault Benoît,Guillermet-Guibert Julie
Funder
Association pour la Recherche sur le Cancer
the Institut National du Cancer
Labex TouCAN
Celgene
Marie Skłodowska-Curie Action (MSCA)/Innovative Training Network (ITN)/European Training Network
Fondation de France
European Reintegration Grant
Reference111 articles.
1. The emerging mechanisms of isoform-specific PI3K signalling;Vanhaesebroeck;Nat. Rev. Mol. Cell Biol.,2010
2. Landscape of phosphatidylinositol-3-kinase pathway alterations across 19 784 diverse solid tumors;Millis;JAMA Oncol.,2016
3. Development of PI3K inhibitors: lessons learned from early clinical trials;Rodon;Nat. Rev. Clin. Oncol.,2013
4. Phase I safety, pharmacokinetic, and pharmacodynamic study of SAR245408 (XL147), an oral pan-class I PI3K inhibitor, in patients with advanced solid tumors;Shapiro;Clin. Cancer Res.,2014
5. A multicenter phase I trial of PX-866, an oral irreversible phosphatidylinositol 3-kinase inhibitor, in patients with advanced solid tumors;Hong;Clin. Cancer Res.,2012
Cited by
113 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献